Vol. 22/No. 06 | OncologyLive

Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer

April 05, 2021

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

A New Crop of ER-Targeting Agents Takes Root

April 02, 2021

Although endocrine therapies have revolutionized the treatment of breast cancers driven by the estrogen receptor, the development of resistance remains a major challenge that limits long-term remission with currently available drugs.

Navitoclax Shows Early Signs of Clinical Benefit in Myelofibrosis

April 01, 2021

The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.